Brief: Inventiva Publishes Phase 2b Native Lanifibranor Results
03/07/2025 06:28
July 3 (Reuters) - IVAA.PA SAID ON WEDNESDAY: END OF TREATMENT BIOPSIES FROM PHASE 2B NATIVE SHOWED IMPROVEMENT IN LSEC CAPILLARIZATION IN PATIENTS WITH MASH AND TREATED WITH LANIFIBRANOR COMPARED TO PLACEBO TWO PRECLINICAL MODELS SUGGEST LANIFIBRANOR COULD REPRESENT A COMPREHENSIVE THERAPEUTIC APPROACH FOR MASH, FIBROSIS REGRESSION, AND THE PREVENTION OF PROGRESSION TO CIRRHOSIS Source text: https://tinyurl.com/d5vehnrh Further company coverage: IVAA.PA (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Inventiva SA
See all newsFrance's Inventiva H1 net loss narrows
Brief: Euronext Includes Genfit, Inventiva In SBF120 Index; Interparfums, Verallia Excluded
Brief: Inventiva Announces Last Patient Visit In Nativ3 Phase 3 Clinical Trial Of Lanifibranor In Mash
Brief: Inventiva Announces Comprehensive Capital Structure Optimization Including Debt And Equity Financing In Advance Of The Anticipated Phase 3 Readout
Brief: Inventiva Secures Up To €150 Mln Debt Financing, Extends Debt Maturity To 2030